M24-108 A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of Etentamig (ABBV-383) in Subjects with Relapsed or Refractory Multiple Myeloma

  • Phase I
  • Trial Category: Hematologic

Contact(s)

Mary Beth Wilwerding, RN   Admin@NEcancertrials.com

Location(s)

Available at Nebraska Cancer Specialists, Omaha and Grand Island, NE locations  and at Nebraska Hematology and Oncology, Lincoln, NE location

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*